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Abstract
Regulators of G-protein Signaling (RGS) proteins attenuate signaling activities of G proteins, and modulation of
expression appears to be a primary mechanism for regulating RGS proteins. In human astrocytoma 1321N1 cells RGS2
expression was increased by activation of muscarinic receptors coupled to phosphoinositide signaling with carbachol, or by
increased cyclic AMP production, demonstrating that both signaling systems can increase the expression of a RGS family
member in a single cell type. Carbachol-stimulated increases in endogenous RGS2 protein levels appeared by
immunocytochemical analysis to be largely confined to the nucleus, and this localization was confirmed by Western blot
analysis which showed increased nuclear, but not cytosolic, RGS2 after carbachol treatment. Additionally, transiently
expressed green fluorescent protein (GFP)-tagged, 6UHis-tagged, or unmodified RGS2 resulted in a predominant nuclear
localization, as well as a distinct accumulation of RGS2 along the plasma membrane. The intranuclear localization of GFP-
RGS2 was confirmed with confocal microscopy. Thus, RGS2 expression is rapidly and transiently increased by
phosphoinositide signaling and by cyclic AMP, and endogenous and transfected RGS2 is largely, although not entirely,
localized in the nucleus. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Receptors coupled to heterotrimeric G proteins
initiate intracellular signaling by facilitating the ex-
change of GTP for GDP on the G-protein K-sub-
unit. The GTP-bound K-subunit dissociates from
the LQ-subunits and interacts with e¡ectors. The ac-
tivity of the GTP-K-subunit complex is terminated
by an intrinsic GTPase activity of the K-subunit,
which cleaves GTP to GDP. Recent evidence indi-
cates that the rate of the GTPase activity is en-
hanced by Regulators of G-protein Signaling
(RGS) family members [1^3]. Hence, it appears
that RGS proteins are critical regulators of signaling
activities emanating from G-protein-coupled recep-
tors.
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The actions of RGS proteins are regulated in
part by control of their expression. The expression
of RGS2, one of the ¢rst RGS proteins discovered
[4,5], is regulated by neuronal activity [6], by cer-
tain psychotropic agents [6^8], and by receptor-
coupled second messenger systems [9^12]. For ex-
ample, in human neuroblastoma SH-SY5Y cells
stimulation of muscarinic receptors coupled to the
phosphoinositide signal transduction system caused
rapid and transient increases in RGS2 mRNA lev-
els in a protein kinase C-dependent manner [11].
However, cell type-selectivity in the mechanisms
regulating RGS2 expression are evident, since phor-
bol ester-induced activation of protein kinase C did
not increase RGS2 mRNA levels in blood mono-
nuclear cells [13]. RGS2 mRNA levels also have
been reported to be increased by elevation of cyclic
AMP in PC12 cells, human embryonic kidney cells,
and T cells [9,10,14], but not in human neuroblas-
toma SH-SY5Y cells [11]. Cell type-selective regu-
lation of RGS2 expression also was found in stud-
ies using the calcium ionophore ionomycin, which
increased RGS2 mRNA in blood mononuclear cells
[13] but not in PC12 cells [9]. The regulation
of RGS2 expression by a variety of agents suggests
that modulation of RGS2 expression may be an
important mechanism by which cells regulate
RGS2 function.
> The present study extends previous investigations
of the regulation of RGS2 expression by signaling
systems. These experiments used human astrocyto-
ma 1321N1 cells because they endogenously express
both muscarinic receptors linked to the phosphoino-
sitide signal transduction system and L-adrenergic
receptors coupled to the production of cyclic
AMP. The results show that RGS2 mRNA levels
are increased both by carbachol-induced muscarinic
receptor activation and by stimulation of cyclic
AMP production. The RGS2 protein level also was
shown to increase after carbachol stimulation, and
immunocytochemistry and immunoblots revealed
that the increased endogenous RGS2 protein was
predominantly localized in the nucleus. The predom-
inant nuclear localization of RGS2, as well as accu-
mulation along the plasma membrane, also was evi-
dent after transient transfection of RGS2, and the
nuclear localization was con¢rmed by confocal mi-
croscopy.
2. Materials and methods
2.1. Cell culture
Human astrocytoma 1321N1 cells were grown in
Dulbecco’s modi¢ed Eagle’s medium supplemented
with 5% fetal bovine serum (Life Technologies, Gai-
thersburg, MD), 2 mM L-glutamine, 100 units/ml
penicillin and 100 Wg/ml streptomycin. Cells were
maintained in humidi¢ed, 37‡C chambers with 5%
CO2. Experimental agents used include carbachol,
atropine, isoproterenol, phorbol 12-myristate 13-ace-
tate (PMA), from Sigma (St. Louis, MO), and for-
skolin from Alexis Biochemicals (San Diego, CA).
Cyclic AMP levels were measured using a kit accord-
ing to the supplier’s instructions (Amersham, Arling-
ton Heights, IL).
2.2. Northern blots
RGS2 cDNA was generously provided by Dr.
D.R. Forsdyke (Queen’s University, Kingston, On-
tario, Canada). Total RNA was extracted using Tri-
zol reagent (Life Technologies) according to the
manufacturer’s instructions. RNA (15 Wg) was sepa-
rated by electrophoresis in 1.2% agarose gels contain-
ing formaldehyde and transferred to nitrocellulose
membranes. cDNA was random prime-labeled with
[32P]dCTP (Amersham Pharmacia Biotech). Blots
were hybridized with labeled probes at 42‡C for 18
h and then washed in two changes of 2U saline-so-
dium citrate and 0.1% sodium dodecyl sulfate (SDS)
at 20‡C for 20 min and once in 1U saline-sodium
citrate and 0.1% SDS at 55‡C for 10 min. Results
were obtained using a PhosphorImager (Molecular
Dynamics, Sunnyvale, CA), and bands were quanti-
tated using ImageQuant.
2.3. Immunocytochemistry of endogenous RGS2
1321N1 cells were cultured in four-well Lab-Tek II
Chamber slides (Nalge Nunc International, Naper-
ville, IL). To identify endogenous RGS2 protein,
cells were treated with 1 mM carbachol, 100 WM
isoproterenol, or 10 WM forskolin. Cells were ¢xed
with 2% paraformaldehyde, 0.2% glutaraldehyde in
phosphate-bu¡ered saline (PBS) for 30 min, rinsed
with PBS, and permeabilized with 2% Triton X-100
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in PBS for 2 min at room temperature. After block-
ing endogenous peroxidase and biotin (Avidin/Biotin
Blocking kit, InnoGenex, San Roman, CA), cells
were rinsed with 0.1% Triton X-100 in Tris-bu¡ered
saline (TBS; 30 mM Tris, 120 mM NaCl, pH 7.4)
and incubated overnight at 4‡C with anti-RGS2
phage antibody 19.4 (1:200; obtained from phage
display using RGS2 as the antigen as described
[15]) biotinylated with Biotin Labeling Reagent (In-
noGenex) according to the manufacturer’s protocol.
To verify the detection of RGS2, the biotin-labeled
19.4 RGS2 antibody was preincubated with recombi-
nant RGS2 at 4‡C for 2 h before application to
samples that had been treated with carbachol or for-
skolin. Cells were washed with TBS-T (TBS with
0.1% Triton X-100), horseradish peroxidase^strept-
avidin conjugate (InnoGenex) was added (1:40),
and cells were incubated for 2 h at room temper-
ature. Cells were rinsed with TBS-T, developed at
room temperature with DAB (Diaminobenzidine; In-
novex, Richmond, CA) and nuclei were counter-
stained with hematoxylin I (Richard Allen Scienti¢c,
MI) for the data in Fig. 4A or cells were stained with
eosin (Richard Allen Scienti¢c) for the data shown in
Fig. 4C.
2.4. Plasmids
Green £uorescent protein (GFP)-tagged RGS2,
6UHis-tagged RGS2, and unmodi¢ed RGS2 were
expressed, and expressed proteins were detected us-
ing antibodies recognizing GFP, 6UHis, or RGS2.
Full-length RGS2 cDNA was ampli¢ed by polymer-
ase chain reaction (PCR) from pBR322/RGS2 DNA
(primers: 5P-AGAGTCGACATGCAAAGTGCTA-
TGTTCTT-3P and 5P-GGTGGATCCCTCGAGA-
TGTAGCATGAGG-3P), digested with SalI and
SmaI, and inserted into the SalI/SmaI sites of
the pEGFP vector (Clontech, Palo Alto, CA) to
make pEGFP/RGS2. For construction of pET28-
B(+)/6UHisRGS2, full-length RGS2 cDNA was am-
pli¢ed by PCR from pBR322/RGS2 DNA (primers:
5P-AGAGTCGACATGCAAAGTGCTATGTTCTT-3P
and 5P-TATGCGGCCGCACAGTCCTTCCCCTC-
AG-3P), digested with SalI and NotI, and inserted
into the NotI and SalI restriction sites of
pET28b(+) (Novagen, Madison, WI). The RGS2 se-
quence derived from pET28b(+)/RGS2 by BamHI/X-
hoI digestion was inserted into the BamHI/XhoI re-
striction site of pcDNA3.1(+) (Invitrogen, Carlsbad,
CA). The 6UHis-tagged RGS2 sequence was excised
from pET28b(+)/6UHis-RGS2 and inserted in the
XbaI/XhoI restriction sites of pcDNA3.1(3) (Invitro-
gen). All plasmids were veri¢ed by DNA sequencing.
2.5. Imaging of transfected RGS2
Cells were grown on poly-D-lysine/laminin-coated
coverslips and transiently transfected with pEGFP-
RGS2, pEGFP, pcDNA3.1(3)/6UHis-RGS2, or
pcDNA3.1(+)/RGS2 using Fugene6 (Roche) accord-
ing to the manufacturer’s protocol. After 24 h, cells
were washed with PBS, and ¢xed with 2% paraform-
aldehyde, 0.2% glutaraldehyde in PBS for 30 min at
room temperature. Cells were rinsed with 0.1% Tri-
ton X-100 in PBS, permeabilized with 2% Triton X-
100 in PBS for 2 min, and incubated for 30 min with
2% BSA/PBS with 0.1% Triton X-100 at room tem-
perature. Primary antibodies to RGS2 (C-18 (1:50;
Santa Cruz) or phage antibody 19.4 (1:50)) were
added and samples were incubated overnight at
4‡C with 5% BSA/TBS-T. After washing with PBS-
T, secondary antibodies were added (anti-
FLAG(M2)-FITC (1:200; Sigma) or anti-goat IgG-
FITC (1:200; Jackson ImmunoResearch Laborato-
ries, West Grove, PA)). After incubation for 1 h at
room temperature, cells were washed with 0.1% Tri-
ton X-100 in PBS. To identify nuclei, cells were in-
cubated with 1 Wg/ml DAPI for 10 min at room
temperature. Cells were examined with a Nikon Dia-
phot 200 Epi£uorescence microscope and an Olym-
pus confocal scanning microscope.
2.6. Preparation of nuclear and cytosolic fractions and
immunoblotting
To prepare nuclear and cytosol fractions, cells
were washed two times with PBS and were lysed
with 500 Wl lysis bu¡er (10 mM Tris^HCl (pH 7.4),
10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 1 Wg/ml
leupeptin, 1 Wg/ml aprotinin, 1 Wg/ml pepstatin A,
1 mM phenylmethylsulfonyl £uoride). Lysates were
centrifuged at 4000Ug for 5 min at 4‡C. The super-
natant was transferred, and nuclear proteins were
extracted from the pellet with 20 mM HEPES (pH
7.9), 0.35 mM NaCl, 20% glycerol, 1.5 mM MgCl2,
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0.2 mM EDTA, 0.1 mM L-glycerophosphate, 1 Wg/
ml leupeptin, 1 Wg/ml aprotinin, 1 Wg/ml pepstatin A,
1 mM phenylmethylsulfonyl £uoride. After extrac-
tion on ice for 30 min incubation, insoluble material
was removed by centrifugation at 16 000Ug for 15
min at 4‡C. Protein concentrations were determined
using the BCA assay (Pierce, Rockford, IL). Samples
were mixed with Laemmli bu¡er (2% SDS) and
placed in a boiling water bath for 5 min. Proteins
(50 Wg) were resolved in 12% SDS^polyacrylamide
gels, and transferred to nitrocellulose. Membranes
were blocked with 5% milk in TBS-T for 1 h and
then probed with anti-RGS2 phage antibody 19.4
(1:500), followed by incubation with horseradish per-
oxidase-conjugated anti-FLAG(M2) (1:2000) sec-
ondary antibody (Sigma). Immunoblots were devel-
oped using enhanced chemiluminescence with Super
Signal (Pierce).
3. Results
3.1. Muscarinic receptor activation and cyclic AMP
increase RGS2 mRNA levels in 1321N1 cells
RGS2 mRNA levels were measured in human as-
trocytoma 1321N1 cells to test if expression was
regulated by activation of either the phosphoinositide
or cyclic AMP second messenger systems, signaling
cascades previously found to increase RGS2 mRNA
levels in other cell types [9^11,14]. Activation of both
signal transduction systems increased RGS2 mRNA
levels in 1321N1 cells. Stimulation of muscarinic re-
ceptors coupled to the phosphoinositide signal trans-
duction system with 1 mM carbachol caused a rapid
and large increase in RGS2 mRNA levels (Fig. 1).
The RGS2 mRNA level almost doubled within 15
min of carbachol treatment, maximal increases that
were 8- to 10-fold the basal level were attained within
1 h, and levels remained elevated by several-fold for
at least 4 h. Pretreatment with the speci¢c muscarinic
receptor antagonist atropine (1 WM) completely
blocked the carbachol-induced increase in RGS2
mRNA, and actin mRNA levels were una¡ected by
treatment with carbachol. Forskolin, an activator of
adenylyl cyclase, was used to increase cyclic AMP
production. Treatment with 10 WM forskolin for 1 h
caused cyclic AMP levels to increase 3.5-fold, from a
basal level of 96 þ 20 to 350 þ 76 nmol/Wg protein
(means þ S.E.M.; n = 4). After treatment with 10 WM
forskolin, there was a time-dependent increase in
RGS2 mRNA levels which reached a maximal
4-fold elevation that was maintained from 1 to 2 h
after treatment (Fig. 2). 1321N1 cells endogenously
express L-adrenergic receptors that are linked to ac-
tivation of adenylyl cyclase [16]. Activation of these
receptors with the selective agonist isoproterenol also
increased RGS2 mRNA levels (Fig. 3). Increases in
RGS2 mRNA levels were evident within 30 min after
Fig. 1. RGS2 mRNA levels in 1321N1 cells are increased by
stimulation of muscarinic receptors with carbachol. RGS2 and
actin mRNA levels were measured in 1321N1 cells treated with
1 mM carbachol (Carb) for 15 min to 24 h. Pretreatment with
1 or 10 WM atropine (A1 and A10, respectively) for 10 min
blocked the increase in RGS2 mRNA caused by treatment with
1 mM carbachol for 60 min. Results shown are representative
of two independent experiments.
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treatment with isoproterenol, and a maximum in-
crease that was almost 400% of the basal level was
attained after 1 h. Thus, both stimulation of endog-
enous muscarinic receptors that are coupled to the
phosphoinositide signal transduction system and ac-
tivation of cyclic AMP production caused rapid, sub-
stantial, and transient increases in RGS2 mRNA lev-
els in 1321N1 cells. These ¢ndings demonstrate that
each of these two major second messenger systems
can increase the expression of a single member of the
RGS family in a single type of cell.
3.2. Intracellular localization of RGS2
The intracellular localization of endogenous RGS2
was assessed immunocytochemically. Little RGS2
was detected in untreated 1321N1 cells (Fig. 4A).
Treatment with 1 mM carbachol for 1, 2, and 4 h
caused a time-dependent increase in RGS2 protein
levels (Fig. 4A). Thus, RGS2 protein, as well as
mRNA, levels were increased by treatment with car-
bachol. Much, but not all, of the RGS2 appeared to
be present in the nucleus after treatment with carba-
chol. This was con¢rmed by Western blot analyses of
cytosolic and nuclear extracts prepared from control
cells and from cells treated with carbachol for 2.5 h
(Fig. 4B). RGS2 was undetectable in the cytosolic
fraction, whereas carbachol treatment resulted in a
large increase in RGS2 in the nuclear fraction. Im-
munocytochemical detection was also used to com-
pare the increases in endogenous RGS2 protein level
resulting from treatment with isoproterenol, forsko-
lin, and carbachol, assessed 2.5 h after each treat-
ment (Fig. 4C). The increase in RGS2 protein level
induced by isoproterenol treatment appeared lower
than after treatment with the other agents, whereas
the magnitudes of the responses to carbachol and
forskolin were similar. Preabsorbtion of the RGS2
antibody with recombinant RGS2 completely elimi-
Fig. 3. L-Adrenergic receptor activation by isoproterenol in-
creases RGS2 mRNA levels. 1321N1 cells were treated with
100 WM isoproterenol for 30^180 min, and RGS2 and actin
mRNA levels were measured by Northern blot analysis. Means
þ S.E.M. (n = 3).
Fig. 2. Forskolin treatment increases RGS2 mRNA levels in
1321N1 cells. 1321N1 cells were treated with 10 WM forskolin
(FSK) for 30^180 min, and RGS2 and actin mRNA levels were
measured by Northern blot analysis. Means þ S.E.M. (n = 4).
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nated detection of increases after treatment with car-
bachol and forskolin (Fig. 4D), con¢rming the iden-
tity of the observed stimulus-induced increases in
RGS2.
To further examine the intracellular localization of
RGS2, cells were transiently transfected with GFP-
RGS2, 6UHis-RGS2, or unmodi¢ed RGS2. The in-
tracellular localization of GFP-tagged RGS2 was de-
Fig. 4.
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termined by epi£uorescence and confocal microsco-
py. Fig. 5A shows that there was a distinct nuclear
accumulation of GFP-RGS2 as well as a concentra-
tion along the plasma membrane, whereas less ap-
peared to be free in the cytosol. Identical results
were obtained with both N-terminal and C-terminal
GFP-tagged RGS2 (data not shown). Confocal mi-
croscopy (Fig. 5B) con¢rmed that GFP-RGS2 was
located within nuclei. Additionally, GFP-RGS2 was
evident lining the plasma membrane in the confocal
Fig. 4. Treatment of 1321N1 cells with carbachol, isoproterenol, or forskolin increased the levels of RGS2. (A) 1321N1 cells in four-
well chambers were treated with 1 mM carbachol for 0, 1, 2, or 4 h. The ¢rst panel shows images of matched untreated cells. Cells
were ¢xed and stained with biotin-labeled anti-RGS2 antibody 19.4, as described in Section 2. Nuclei were counterstained with hema-
toxylin I. The results demonstrate that treatment with carbachol increased the expression of endogenous RGS2 and that RGS2 is pre-
dominantly in the nucleus. (B) Cytosolic and nuclear fractions were prepared from control 1321N1 cells and from cells treated with
carbachol for 2.5 h. Proteins were resolved by electrophoresis, transferred to nitrocellulose, and immunoblotted for RGS2. The last
lane shows an immunoblot of total cell extract obtained from cells transiently expressing RGS2. (C) 1321N1 cells in four-well cham-
bers were untreated (Control) or treated with 100 WM isoproterenol, 1 mM carbachol, or 10 WM forskolin for 2.5 h. Cells were ¢xed
and stained with biotin-labeled anti-RGS2 antibody 19.4 and eosin, as described in Section 2. (D) 1321N1 cells were untreated (Con-
trol) or treated with 1 mM carbachol or 10 WM forskolin for 2.5 h. Cells were ¢xed and control cells were stained with biotin-labeled
anti-RGS2 antibody 19.4, and carbachol- and forskolin-treated cells were stained with biotin-labeled anti-RGS2 antibody 19.4 that
was preabsorbed with puri¢ed recombinant RGS2. The top panel shows cells stained with hematoxylin I and the lower panel shows
cells stained with eosin. The results show that preabsorption of the RGS2 antibody with excess RGS2 eliminated the detection of in-
creased RGS2 protein induced by carbachol or by forskolin.
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images. Unmodi¢ed expressed RGS2 detected with
anti-RGS2 antibody 19.4 (Fig. 5C), or 6UHis-
RGS2 detected with anti-RGS2 antibody C-18 (Fig.
5D) also was predominantly nuclear. Taken together,
regardless of the form of RGS2 that was expressed
and the means of detection, RGS2 was consistently
primarily distributed in the nucleus and along the
plasma membrane.
4. Discussion
The signaling actions of G-protein-coupled recep-
tors are now known to be regulated in part by mem-
bers of the RGS family of proteins [1^3]. Considering
the abundance and importance of G-protein-coupled
receptors in mammalian cells, regulatory in£uences
on the expression and function of RGS proteins
are likely to have a signi¢cant impact on cell func-
tion. This investigation found that both the phos-
phoinositide and cyclic AMP signaling systems can
increase RGS2 mRNA levels in a single type of cell,
and intracellular RGS2 was observed to be predom-
inantly localized to the nucleus and along the plasma
membrane. The rapid and transient increases in
RGS2 expression following stimulation of G-pro-
tein-coupled receptors suggest that the RGS2 serves
a vital role in cell function. This may derive from the
ubiquitous use by cells of G-protein-coupled recep-
tors to mediate responses to extracellular stimuli and
the necessity to control these responses through the
actions of RGS proteins, as well as other functions
of RGS proteins yet to be discovered as suggested by
the ¢nding that both endogenous and overexpressed
RGS2 was observed in the nucleus as well as at the
plasma membrane.
RGS2 mRNA levels were increased in 1321N1
cells after stimulation of muscarinic receptors that
are coupled to the phosphoinositide signal transduc-
tion system and after treatments that activate adenyl-
yl cyclase to increase cyclic AMP production. This is
not the ¢rst time that each of these signaling systems
has been found to increase RGS2 expression, as re-
viewed in the Introduction, but it is the ¢rst time that
both signaling systems have been found to activate
the expression of any RGS family member in a single
cell type. With current indications that there are
likely G-protein-subtype speci¢cities in the actions
of each member of the RGS family [3], there might
be an expectation of a correspondence between the
RGS protein’s target and the signaling systems that
regulate the expression of an RGS protein. However,
the present results indicate that this is not the case
since RGS2 has been reported to selectively interact
with the phosphoinositide signaling system-linked G
proteins Gq/11 but not with the adenylyl cyclase-
linked G-protein Gs [3,17,18]. However, it has also
become evident that in addition to acting as GTPase-
activating proteins, RGS proteins are also e¡ector
antagonists. Recently, RGS2 was found to attenuate
activation of adenylyl cyclase independently of its
GTPase-activating actions [19]. Taken together, it is
evident from these results that the identity of signal-
ing systems that regulate the expression of RGS fam-
ily members is not likely to be predictable based on
the RGS target G proteins. However, it appears
likely that regulated expression of RGS2 may play
an important role in cross-talk between second mes-
senger systems, and thus in the regulation of neuro-
nal plasticity. There is much evidence that the phos-
phoinositide and cyclic AMP signaling systems cross-
regulate one another (e.g., [20^22]). Thus, up-regula-
tion of RGS2 expression by both phosphoinositide
signaling and by cyclic AMP provides a potential
mechanism for each signaling system to transiently
modulate the activity of the other. Such a mechanism
may be important in the temporal integration of sig-
naling activities, modulating both the magnitude and
duration of signals, properties important for infor-
mation processing in neural networks [23].
Fig. 5. Nuclear and plasma membrane localization of GFP-RGS2. (A) 1321N1 cells were transiently transfected with the pEGFP/
RGS2 plasmid 24 h prior to imaging. The left panel shows green £uorescence (GFP-RGS2) image, the middle panel shows blue
DAPI-stained nuclei, and the right panel shows merged images. (B) Confocal images of representative 1321N1 cells after transient
transfection with pEGFP/RGS2. The images of 1321N1 cells display layers analyzed from the bottom to the top at 0.4-Wm intervals,
and a merged image. (C) Transiently expressed RGS2 detected with anti-RGS2 antibody 19.4. (D) Transfected 6UHis-RGS2 detected
with anti-RGS2 antibody C-18. Panels show FITC, DAPI, and merged images. In all cases, RGS2 was detected predominantly in the
nucleus and along the plasma membrane.
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Until recently, most reports of the intracellular
localization of members of the RGS family of pro-
teins used subcellular fractionation methods and
found RGS proteins associated with the membrane
fraction or distributed between the membrane and
cytosolic fractions (e.g., [24,25]). However, recently
there have been several reports noting the nuclear
localization of RGS proteins [26^29]. For example,
predominant nuclear localization was observed after
expression of a myc-tagged truncated variant of
RGS3, RGS3T, in CHO cells [27], of GFP-tagged
RGS2 and RGS10, but not RGS4 and RGS16, in
COS-7 cells [28], and some splice variants of
RGS12 also showed predominantly nuclear localiza-
tion [29]. In the present study, RGS2 also was con-
sistently observed to be concentrated in the nucleus,
along with an accumulation along the plasma mem-
brane. Endogenous RGS2 expressed in response to
stimulation of 1321N1 cells with carbachol was most
prevalent in nuclei. Additionally, a consistent accu-
mulation of RGS2 in the nucleus was observed fol-
lowing expression of GFP-RGS2, 6UHis-RGS2, or
unmodi¢ed RGS2 in 1321N1 cells. Furthermore, ex-
amination of cells expressing GFP-RGS2 with con-
focal microscopy con¢rmed that the GFP-RGS2 was
within the nucleus, not bound to the cytosolic face of
the membrane. The RGS2 enrichment at the plasma
membrane is consistent with the interactions of
RGS2 with membrane-bound heterotrimeric G pro-
teins. However, the nuclear localization of RGS2, as
well as of other RGS proteins [26^29], raises the
possibility that they contribute more to cellular func-
tions than solely as regulators of receptor-coupled
heterotrimeric G-protein signaling activities.
In summary, the expression of RGS2 was found to
be subject to rapid regulation by the phosphoinosi-
tide and cyclic AMP second messenger systems. Fur-
thermore, an increase in the RGS2 protein level was
shown to follow stimulation of muscarinic receptors.
The functional impacts of these changes in RGS2
expression remain to be established, but in addition
to regulating the activities of G proteins there may
be other, as yet undiscovered, actions of RGS2 which
are associated with its nuclear localization. Taken in
conjunction with the unique mechanisms regulating
RGS2 expression (e.g., [6]), it appears possible that
RGS2 has specialized functions underlying its sensi-
tivity to controlled expression by a wide variety of
stimuli, and its localization in the nucleus.
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